Stichting Health Action International

Tweet this page
Registration as it was on 14 Mar 2023
How to read and use this data card.
Download this datacard


Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.

Lobbying Costs

None declared

Financial year: Jan 2021 - Dec 2021

Lobbyists (Full time equivalent)

2.75 Fte (5)

Lobbyists with EP accreditation


High-level Commission meetings


Lobbying Costs over the years

  • Info

    Stichting Health Action International   (HAI)

    EU Transparency Register

    44361352681-84 First registered on 30 Nov 2009

    Goals / Remit

    Health Action International is a non-profit, independent global network of consumer groups, public interest NGOs, healthcare professionals, academics, and individuals working and interested on pharmaceutical policy issues. HAI’s mission is to increase equitable access to essential medicines and improve their rational use through research excellence and evidence-based advocacy.

    In Europe, HAI has grown to become a pre-eminent voice in medicines policy intervention/discussion, supported by a strong European network of 125 individual and organization members from 19 European Union (EU) Member States and 14 other non-EU countries. The HAI Europe projects team, based in Amsterdam, is responsible for coordinating the work programmed and related activities within the European region. HAI monitors and advocates on EU policies that affect medicines on three key thematic priorities: Access to Needed Medicines, the Rational Use of Medicines, and the Democratization of Medicines Policy.

    Main EU files targeted

    HAI advocates for policy initiatives that help to address current shortfalls/shortcomings in access to medicines. In Europe, HAI monitors EU policy initiatives and developments that have an impact on access to medicines, their rational use and on the democratization of medicines policy. We also work on exposing major risks that the use of Artificial Intelligence (AI) in health can cause, including discrimination, harming citizens health and safety, and the exacerbation of health inequalities, which infringes on patients’ fundamental rights. Where needed, we issue recommendations for improvement on specific topics. EU legislation, policies and initiatives of particular interest include: implementation of proposals on EU cooperation on Health Technology Assessment and clinical trials regulation; discussion of European Pharmaceutical Strategy and review of EU pharmaceutical legislation, orphan designation and other IP incentives; European Union IP Action Plan and enforcement strategy, including revision of Supplementary Protection Certificate Regulation; Competition policy; EU trade agreements with impact on access to medicines; Innovative Medicines Initiative and Horizon Europe; Multiannual Financial Framework (MFF); implementation of the One Health Action Plan against AMR; European Medicine Agency (EMA)'s policies and activities; tackling medicines shortages.


    Head Office
    Overtoom, 60/II
    Amsterdam 1054HK
    EU Office
    Overtoom, 60/II
    Amsterdam 1054HK


  • People

    Total lobbyists declared


    Employment timeLobbyists

    Lobbyists (Full time equivalent)


    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    2 accreditations were / are live (in bold) for the selected state of 04 Dec 2023

    Name Start date End Date
    Ms Hannah VAN KOLFSCHOOTEN 14 Dec 2022 13 Dec 2023
    Ms Janneke VAN OIRSCHOT 09 Dec 2022 08 Dec 2023
    Mr Jaume VIDAL 04 Nov 2022 04 Nov 2023
    Ms Ellie WHITE 27 Oct 2021 11 Feb 2022
    Mr Jaume VIDAL 27 Oct 2021 27 Oct 2022
    Mr Jaume VIDAL 19 Sep 2019 19 Sep 2020
    Ms Ellie WHITE 14 Sep 2019 12 Sep 2020
    Ms Ancel·la Santos Quintano 13 Oct 2018 25 Apr 2019
    Mr Jaume VIDAL 13 Oct 2018 19 Sep 2019
    Ms Ancel·la Santos Quintano 14 Oct 2017 13 Oct 2018
    Mr Jaume VIDAL 20 Jul 2017 07 Jul 2018
    Ms Tessel Mellema 07 Sep 2016 21 Jul 2017
    Ms Ancel·la Santos Quintano 07 Sep 2016 07 Sep 2017
    Ms Tessel Mellema 27 Aug 2015 26 Aug 2016
    Ms Ancel·la Santos Quintano 27 Aug 2015 26 Aug 2016
    Ms Aliénor Devalière 27 Aug 2015 23 Jun 2016
    Ms Ancel·la Santos Quintano 01 May 2014 05 Jun 2015
    Ms Aliénor Devalière 07 Jun 2014 05 Jun 2015
    Mrs Aliénor Devalière 07 Jun 2014 27 Jan 2015
    Ms Tessel Mellema 01 May 2014 05 Jun 2015
    Mrs Ancel·la Santos Quintano 01 May 2014 27 Jan 2015
    Ms Tessel Mellema 25 Jun 2013 01 May 2014
    Mrs Ancel·la Santos Quintano 30 May 2013 01 May 2014
    Ms Katrina Perehudoff 22 Sep 2012 17 Jun 2013
    Ms Tessel Mellema 20 Sep 2012 25 Jun 2013

    Complementary Information

    HAI has one full-time policy advisor that is solely focused on our EU projects. He is supported by Admin, Communications, PME & our Executive Director.

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories


    Non-governmental organisations, platforms and networks and similar

  • Networking


    HAI is a member of the European Public Health Alliance (EPHA), the International Society of Drug Bulletins (ISDB), the Transatlantic Consumer Dialogue (TACD), the Medicines in Europe Forum (MiEF), the European Alliance for Responsible R&D and Affordable Medicines, the Antimicrobial Resistance Coalition, and Global Snakebite Initiative. In addition, HAI enters into strategic partnership with other associations when collaborating on certain topics thus tapping into extended expertise as required.

    HAI is also a member of the EMA’s Patients and Consumers Working Party (PCWP), EPWG on Access to Medicines and Poverty-related Diseases (co-chair), EMA PRAC Multistakeholder Drafting Group for Reflection Paper on Digital Support to Risk Minimisation Measures and Their Effectiveness Evaluation and leads a Thematic Network on AI and Health Inequalities on the EU Health Policy Platform .

    HAI is in official relations with the WHO and collaborates with the organization on several projects as well as attending governing bodies and ad-hoc meetings.

    EU Pharmaceutical Strategy
    National Action Plans of Member States on Anti-Microbial Resistance
    (TRIPS +) IP measures, particularly transferable exclusivity vouchers
    TRIPS Waiver proposal
    European Health- Data Space and the EMA / HMA Big Data Workplan
    The EU Artificial Intelligence Act
    The EU AI Liability Directives
    The EU Medical Devices Regulation
    European Health Data Space
    HAI Europe Association

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Does not represent commercial interests

    Closed financial year

    Jan 2021 - Dec 2021

    Lobbying costs for closed financial year

    Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.

    Total organisational budget in closed year


    Major funding types in closed year

    EU funding, Public financing, Member's contribution, Grants

    Major contributions in closed year

    Contribution Helmsley Charitable Trust 930,712€
    Contribution European Commission/HADEA 213,692€
    Contribution Perls Foundation 34,852€
    Contribution European Artificial Intelligence Fund 52,181€
    Contribution Hennecke Foundation 98,762€
    Contribution Lillian Lincoln Foundation 113,184€
    Contribution Open Society Foundations 64,016€
    Contribution Waterloo Foundation 53,029€
    Contribution Dutch Ministry of Foreign Affairs 22,958€
    Contribution IDA Charity Foundation 92,500€
    Contribution UNITAID 99,828€
    Contribution Embassy of the Kingdom of the Netherlands in Burundi 115,440€
    Grant European Commission/HADEA 213,692€

    Major contributions in current year

    Grant European Commission INTPA 731,854€

    Other financial info


  • EU Structures

    Groups (European Commission)


    Groups (European Parliament)

    Artificial intelligence and digital

    Communication activities

    For our publications please visit:
    For our press releases and other news please visit:

    In 2022, we released 12 publications and hosted a number of events and meetings to discuss and disseminate these. These publications, including policy briefs, statements and reports, formed the basis of our advocacy work. In the same period, our European project work and staff were quoted pr mentioned in the media no less than 35 times, demonstrating the added value of our published materials and that our staff are seen by media contacts as experts in their field. The European Projects Team has worked closely with the HAI Communications Team to develop engaging content that promoted our work and helped achieve project objectives. One major addition to the work and objectives of the team was the launch of the TRIPS Flexibilities Navigator, a living resource designed to help to educate lawmakers, policymakers, researchers, and the public about how the use of TRIPS Flexibilities as a legitimate tool to improve access to patented medicines. Currently, the navigator boasts over 120 users, with plans for expansion in 2023.

    Other activities

    HAI is a member of the European Medicines Agency Patients' and Consumers' Working Party (PCWP); and a member of the HTA Network Stakeholder Pool.

  • Meetings


    5 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't publish information about such meetings. All information below comes from European Commission web pages.

Download this datacard